ADMP:"FDA Accepts for Review Adamis' New Drug Application for Its Epinephrine Pre-Filled Syringe"
Dr. Dennis Carlo, President and CEO of Adamis, stated, "This is a major milestone in that the PFS will be the company's first product to generate revenues. With the FDA's acceptance of our submission, we are anticipating the regulatory decision for marketing authorization for the PFS in the U.S. in the first half of 2015."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.